Basic Science and Pathogenesis

• Published in: Alzheimer's & dementia Vol. 20 Suppl 1; p. e092632
• Main Authors: Xie, Yuhan, Meng, Xue, Li, Tao, Zhang, Haifeng, Zheng, Yaonan, Kim, SangYun, Zhang, Chen, Yu, Xin, Wang, Huali
• Format: Journal Article
• Language: English
• Published: United States 01.12.2024
• Subjects: Aged; Alzheimer Disease - blood; Amyloid beta-Peptides - blood; Biomarkers - blood; Cognitive Dysfunction - blood; Disease Progression; Female; Humans; Male; Neuropsychological Tests - statistics & numerical data
• ISSN: 1552-5279
• DOI: 10.1002/alz.092632

This study aimed to explore the association between amyloid-β oligomerization tendency (OAβ) in plasma and cognitive performance in patients with Alzheimer's disease (AD) and further determine whether plasma OAβ could predict the outcomes of patients with mild cognitive impairment (MCI). The plasma from 727 subjects in a case registry was tested; these subjects included 286 AD patients, 260 MCI patients and 181 normal controls. The multimer detection system (MDS) was used to measure the plasma oligomeric form of Aβ levels. We measured plasma OAβ after spiking synthetic Aβ into plasma and incubation by this MDS technique. Multipoint clinical diagnosis and domain-specific cognitive functions were assessed to investigate the relationship between blood biomarkers and clinical AD progression. Elevated plasma OAβ were strongly correlated with multidomain cognitive performance in patients with MCI and AD. Patients with MCI with high plasma OAβ at baseline demonstrated a higher AD risk (hazard ratio = 1.083, 95% CI 1.032-1.137). Baseline plasma OAβ predicted AD conversion well (AUC = 0.824, 95% CI 0.752-0.897). Plasma OAβ may be a feasible indicator of AD progression in clinical practice and a potential marker in clinical trials.